Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
Day One Biopharmaceuticals, Inc.
Scientific Title
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations